Experts Share with Experts: Transforming Clinical Trials with Machine Learning.
Machine Learning has gained pace and we have witnessed tremendous innovations that seemed to be impossible just a few years ago. In Healthcare we have seen significant improvements in the patient centric experience and yet the patient journey is still a complex and versatile one.
At the heart of the journey lies the effective use of the ever-growing volumes of research, data, and the resulting opportunity to apply machine learning or other types of A.I. Every patient should be empowered and educated on their opportunities to participate in clinical trials that may offer therapies saving or significantly improving their quality of life.
A panel of renowned experts will share their thoughts on the quest to create reliable predictive and prescriptive instruments for the expedited identification and adherence of the right patients for the right trials at the right time, with a particular focus on automating and optimizing parts of the clinical trial process that are currently manual:
· Adapting core technology into disease-specific applications that provide end-users with a unique value
· Sharing best practices on prioritising enrollment, adherence, and patients’ best health outcomes
· Bridging computational and healthcare expertise with data and partnerships with healthcare systems
Speakers
Dr Jonathan Sheffield
CEO
NIHR Clinical Research Network
Panel Moderator
Dr Jonathan Sheffield is Chief Executive of the National Institute for Health Research, Clinical Research Network. This organisation is funded by the Department of Health to support the practical delivery of both academic and commercial clinical research in the NHS, and was responsible for recruiting more than 870,000 patients into clinical studies last year.
In 2009, Jonathan was awarded an OBE for services to the NHS. In 2011 he was elected an Honorary Fellow of the Royal College of Physicians’ Faculty of Pharmaceutical Medicine — its highest honour — for his contribution in the area of clinical research delivery.
Dr Cornelis Winnips
Global Program Clinical Head
Novartis
Dr Cornelis Winnips trained as medical doctor at Amsterdam University. He started in the pharmaceutical industry as clinical research trainee with Ciba-Geigy Netherlands and subsequently moved through different roles in medical, business development and marketing at Ciba/Novartis in Austria and Switzerland. He gained experience in smaller companies as business unit head and CSO. Following sale of a start-up that he co-founded, Cornellis worked as clinical project lead with CSL Behring. He returned to Novartis in Basel asrt the Global Program Clinical Head. He is also a part-time lecturer at the ETH University in Zürich, teaching pharmacy master students on the principles of clinical development.
Dimitris Iliopoulos
Ph.D. Chief Scientific Officer & Co-Founder
Dyania Health
Dr. Iliopoulos is a world-renown expert in the field of drug discovery and quantitative analysis. He was Assistant Professor of Microbiology & Immunology at Harvard Medical School, Associate Professor of Medicine at UCLA David Geffen School of Medicine and Founder/Director of the UCLA Center for Systems Biomedicine funded by the Eli and Edythe Broad Foundation. Leads biomedical data research efforts in Dyania Health for different human diseases, including cancer and autoimmune diseases. He is an expert on identification and development of novel therapeutics using artificial intelligence methods. He has an extensive publication record and awards related to the pathobiology and development of therapeutics for inflammatory diseases. MIT certified on artificial intelligence.
Eirini Schlosser
CEO & Chairman
Dyania Health
Eirini Schlosser is an experienced technology entrepreneur with experience building data science and machine learning applications with a recent focus in the healthcare and clinical research industries. She has been an investor and advisor to >10 healthcare & technology start-ups, former Morgan Stanley M&A (healthcare, technology & consumer teams), has professional certifications in Machine Learning from MIT, and obtained her Masters from London Business School.
Thomas Puyregner
Director, Project Management & Trial Monitoring
Novartis
Thomas Puyregner, currently Director Project Management Office at Novartis, is a leader in the Global Clinical Operation space, bringing 20 years of experience in clinical operation and people development gathered through roles of increasing responsibilities, from CRA to Global Head of Trial Operation for the largest Trial Monitoring organization of the pharmaceutical industry. Truly passionate about how we can transform clinical operations and the life of people running clinical trials, his experience includes developing data-driven solutions that truly help. Most recently, Thomas brought his extensive business knowledge to game-changing innovations such as predictive analytics, machine learning and artificial intelligence, allowing Novartis to develop solutions to support program and trial level feasibilities, countries and sites allocation strategies, enrolment modelling and mitigations.
